 |
|
|
| |
Safety & Efficacy of Boceprevir/PegInterferon/Ribavirin (BOC/P/R) Combination Therapy for Chronic HCV G1 Patients with Compensated Cirrhosis: A Meta-Analysis of Five Phase 3 Clinical Trials
|
| |
| |
Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
J.M. Vierling1*, S. Zeuzem2, F. Poordad3, J.-P. Bronowicki4, M.P. Manns5, B.R. Bacon6, R. Esteban7, S.L. Flamm8, P.Y. Kwo9, L.D. Pedicone10, W. Deng11, F.J. Dutko11, M.J. DiNubile11, K.J. Koury11, F.A. Helmond11, J. Wahl11, S. Bruno12
1Baylor College of Medicine, Houston, TX, USA, 2JW Goethe University Hospital, Frankfurt, Germany, 3Texas Liver Institute/University of Texas Health Science Center, San Antonio, TX, USA, 4University Henri Poincare of Nancy, Vandoeuvre-lès-Nancy, France, 5Medical School of Hannover, Hannover, Germany, 6Saint Louis University School of Medicine, St. Louis, MO, USA, 7Vall d'Hebron University Hospital, Barcelona, Spain, 8Northwestern Feinberg School of Medicine, Chicago, IL, 9Indiana University School of Medicine, Indianapolis, IN, 10Merck Sharp & Dohme Corp. (former employee), 11Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA, 12A.O. Fatebenefratelli e Oftalmico, Milan, Italy
|
| |
|
|
|
|
|
